Status: Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This open-label extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
Participants needed: 5,700
Trial details
Phase: Phase 3Age: 18-100Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Jul 30, 2026Locations: 643
Eligibility criteria
Participants who have provided informed consent prior to initiation of any study... [+1]
Participants who for any reason permanently discontinued or have interrupted the... [+3]